Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
41. |
ECCT/22/10/04 | IVI-AdCLD-CoV19-1 A Phase IIb Multicenter, Observer-Blinded, Randomized, Placebo-Controlled Trial to Evaluate the Immunogenicity and Safety of the AdCLD-CoV19-1 in Healthy Adults aged 19 years old and above. |
Principal Investigator(s) 1. Fredrick Kipyego Sawe Site(s) in Kenya KEMRI WRP CRC KERICHO |
View |
42. |
ECCT/22/11/03 | BFAST A PHASE II/III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TARGETED THERAPIES AS TREATMENTS FOR PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING ACTIONABLE SOMATIC MUTATIONS DETECTED IN BLOOD (BFAST: BLOOD FIRST ASSAY SCREENING TRIAL) |
Principal Investigator(s) 1. Mansoor Saleh Site(s) in Kenya Aga Khan University, Nairobi |
View |
43. |
ECCT/23/01/04 | ACTIV-2d/A5407 A Phase 3, multicenter, randomized, double-blind, 24-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized participants with COVID-19 |
Principal Investigator(s) 1. Lucas Tina Otieno Site(s) in Kenya 1. MOI UNIVERSITY CLINICAL RESEARCH CENTRE (Uasin Gishu county) 2. Victoria Biomedical Research Institute, (Kisumu county) 3. Kenya Medical Research Institute/Walter Reed Project (Kericho county) 4. Kenyatta National Hospital (Nairobi City county) 5. Ahero Clinical Trials Unit, (Kisumu county) 6. KEMRI CCR – BUTERE SITE (Kakamega county) |
View |
44. |
ECCT/23/01/07 | Moderna 1273 A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age |
Principal Investigator(s) 1. Dr. Lucas Otieno Tina Otieno Tina Site(s) in Kenya 1. Victoria Biomedical Research Institute (Kisumu county) 2. KEMRI/USAMRD (Kericho county) 3. Kenya Medical Research Institute/USAMRU (Kisumu county) 4. KEMRI CMR-Kar Geno Research Centre (Kisumu county) 5. KEMRI CRDR - Clinical Research Nairobi (Nairobi City county) 6. KEMRI/ CDC (Kisumu county) 7. KEMRI (Kisumu county) 8. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county) 9. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county) |
View |
45. |
ECCT/23/02/04 | mRNA-1273-P203 A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age |
Principal Investigator(s) 1. Dr Victor Mudhune Site(s) in Kenya 1. Victoria Biomedical Research Institute (Kisumu county) 2. KEMRI/USAMRD (Kericho county) 3. Kenya Medical Research Institute/USAMRU (Kisumu county) 4. KEMRI CMR-Kar Geno Research Centre (Kisumu county) 5. KEMRI CMR-Kar Geno Research Centre (Kisumu county) 6. KEMRI CRDR - Clinical Research Nairobi (Nairobi City county) 7. KEMRI/ CDC (Kisumu county) 8. KEMRI (Kisumu county) 9. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county) 10. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county) |
View |